Assessing new therapeutic opportunities linked to TCR signalling in mature T-cell lymphomas with unmet need

点击翻译按钮获取中文摘要

Knowledge about the specific molecular and genetic makeup of a patient's tumour provides valuable guide for diagnosis and for decisions about the treatment. This approach, described as personalized or precision medicine, has recognized benefits for patients, drug development and healthcare. However, linking information that describes genetic aberrations in tumours with successful new treatments requires considerable research effort. In this proposal we outline our plan to assess new potential drug targets in T-cell lymphomas where patient's outcome with current treatments remains bleak and where recent genetic studies highlighted changes that could be linked to cancer development. We will combine expertise in a close collabariton that we believe is necessary to provide definitive supporting evidence. This expertise covers long standing involvement in studies of the development of particular forms of T-cell lymphomas and an extensive expertise and contribution to structural and mechanistic understanding of potential targets which will both facilitate ongoing efforts in drug development. This will bring together in-depth insights from studies of isolated proteins, findings from the analysis of cells from actual patient's tumours and initial generation and characterization of potential drugs, all using the latest methodological advances in respective research areas. If confirmed as feasible, the new treatment options will have a wider relevance, including some other cancer types, drug-resistance in specific cancers and a range of immune disorders.